STOCK TITAN

Applied Therapeutics (APLT) Stock News

APLT Nasdaq

Welcome to our dedicated page for Applied Therapeutics news (Ticker: APLT), a resource for investors and traders seeking the latest updates and insights on Applied Therapeutics stock.

Applied Therapeutics Inc. was a clinical-stage biopharmaceutical company focused on rare-disease drug development before its completed acquisition by Cycle Group Holdings Limited. Company news centered on govorestat, a central nervous system-penetrant Aldose Reductase Inhibitor for Classic Galactosemia, CMT-SORD and PMM2-CDG, including FDA interactions, clinical data updates and regulatory strategy.

Other recurring updates covered financial results, strategic alternatives, leadership changes, capital actions and the transaction process that resulted in Applied becoming part of the Cycle group.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
32.62%
Tags
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-40.63%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.37%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.39%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.33%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.14%
Tags
conferences clinical trial
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags

FAQ

What is the current stock price of Applied Therapeutics (APLT)?

The current stock price of Applied Therapeutics (APLT) is $0.103 as of February 3, 2026.

What is the market cap of Applied Therapeutics (APLT)?

The market cap of Applied Therapeutics (APLT) is approximately 14.9M.